gilotrif
(afatinib)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: GILOTRIF is indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations, and for previously treated metastatic squamous NSCLC progressing after platinum-based chemotherapy. Its safety and efficacy in resistant EGFR mutations are not established.